Phosphatidylinositol (PtdIns) is a membrane phospholipid composed of diacylglycerol and a D-myo-inositol head group. In mammals, the hydroxyl groups at the D3, D4 and D5 positions of the inositol ring can be phosphorylated to yield seven phosphoinositide derivatives. 5) P 2 ] is the most recently discovered species of phosphoinositide that is generated by the phosphorylation of PtdIns(3)P at the D5 position by PtdIns phosphate kinase and catabolized through the dephosphorylation by myotubularin family of phosphatases. Genetic and biochemical analyses of the enzymes metabolizing PtdIns(3,5)P 2 have revealed that this phospholipid is involved in the control of endolysosomal systems and plays crucial roles in various mammalian tissues. In this article, we review the current state of knowledge of the metabolic/physiological functions of PtdIns(3,5)P 2 , and describe how disruption of these functions may contribute to human diseases. Phosphatidylinositol-3,5-bisphosphate [PtdIns(3,5)P 2 ] is a membrane phospholipid consisting of diacylglycerol and an inositol ring that is phosphorylated at the D3 and D5 positions (Fig. 1) . In 1997, Dove et al. and Whiteford et al. independently identified PtdIns(3,5)P 2 in extracts of yeast (1) and mouse fibroblasts (2), respectively. These findings brought the number of known phosphorylated derivatives of PtdIns to seven, and provided valuable insights into PtdIns metabolism.
Phosphatidylinositol-3,5-bisphosphate [PtdIns(3,5)P 2 ] is a membrane phospholipid consisting of diacylglycerol and an inositol ring that is phosphorylated at the D3 and D5 positions (Fig. 1) . In 1997, Dove et al. and Whiteford et al. independently identified PtdIns(3,5)P 2 in extracts of yeast (1) and mouse fibroblasts (2), respectively. These findings brought the number of known phosphorylated derivatives of PtdIns to seven, and provided valuable insights into PtdIns metabolism.
Numerous kinases and phosphatases catalyse the phosphorylation and dephosphorylation of hydroxyl residues at the D3, D4 and D5 positions of the inositol. There are 18 phosphoinositide interconversion reactions, which are mediated in mice by 19 phosphoinositide kinases and 28 phosphoinositide phosphatases (3) . The biosynthesis of PtdIns(3,5)P 2 from PtdIns is achieved by two sequential phosphorylation reactions. The first step is phosphorylation at the D3 position of PtdIns, a reaction catalysed predominantly by the class III phosphoinositide 3-kinase Vps34. The second step is phosphorylation at the D5 position of PtdIns(3)P, which is catalysed by type III PtdIns phosphate kinase [PIPKIII; also known as phosphoinositide kinase for five position containing a fyve finger (PIKfyve) in mammals and formation of aploid and binucleate cells (Fab)1p in yeast]. This pathway of PtdIns(3,5)P 2 synthesis appears to be unique because no PtdIns(5)P 3-kinase or PtdIns(3,4,5)P 3 4-phosphatase capable of catalysing any other theoretical pathway of PtdIns(3,5)P 2 synthesis has been reported to date.
The degradation of PtdIns(3,5)P 2 is thought to occur mainly via dephosphorylation at the D3 or D5 position because no phospholipase isolated to date uses PtdIns(3,5)P 2 as a substrate. Sac3 is a PtdIns(3,5)P 2 5-phosphatase that belongs to the Sac phosphoinositide phosphatase family. Each of the other Sac family members, Sac1 and Sac2, has a distinct substrate specificity, and only Sac3 can dephosphorylate PtdIns(3,5)P 2 (3) . Members of the myotubularin-related protein (MTMR) family of phosphatases are plausible candidates for the 3-phosphatase that dephosphorylates the D3 position of PtdIns(3,5)P 2 . Once activated, any of the MTMRs containing the native CX5R phosphatase signature motif, such as, MTM1, MTMR2, MTMR3, MTMR4, MTMR6, MTMR7, MTMR8 and MTMR14, can dephosphorylate the D3 position of PtdIns(3,5)P 2 , as well as PtdIns(3)P, in vitro (3, 4) .
The physiological functions of PtdIns(3,5)P 2 in yeast were originally discovered by studying the phenotypes of mutants lacking Fab1, the yeast orthologue of PIPKIII. Fab1-deficient yeast cells contain grossly enlarged vacuoles which are poorly acidified and show a defect in the ubiquitin-dependent sorting of proteins into multi-vesicular bodies (5). Ent3p, Ent5p, Vps24p and Atg18p have all been identified as PtdIns(3,5)P 2 effectors involved in these yeast membrane trafficking pathways. The detailed physiological functions of PtdIns(3,5)P 2 and the roles of its effectors in yeast have been described in an excellent review (6) . In mammalian cells, functional inhibition of PIPKIII achieved by RNA interference results in enormous enlargement of endosomes. The same phenotype is observed upon overexpression of a kinase-dead PIPKIII mutant, pharmacological inhibition of PIPKIII or PIPKIII deletion by gene targeting (7) . PtdIns(3)P, the substrate of PIPKIII, is localized to early endosomes, reinforcing the theory that PtdIns(3,5)P 2 is also important for mammalian endosomal maturation.
The physiological roles of PtdIns(3,5)P 2 in mammals are not yet well defined, although the association between mutations of genes involved in PtdIns(3,5)P 2 metabolism and various human diseases suggests that PtdIns(3,5)P 2 is essential for diverse processes. This assumption has been supported by analyses of genetically modified mice lacking PtdIns(3,5)P 2 -related molecules. In the next two sections of this review, we describe studies of both human diseases and mouse models that shed light on the physiological functions of PtdIns(3,5)P 2 in mammals.
Human Diseases
Human disorders associated with mutations of genes encoding PtdIns(3,5)P 2 -metabolizing enzymes are listed in Table I . It should be noted that tissue levels of PtdIns(3,5)P 2 in patients with these diseases have not been determined.
Fleck corneal dystrophy
Mutations of the PIPKIII gene can lead to fleck corneal dystrophy (CFD), a rare autosomal dominant corneal dystrophy characterized by the scattering of tiny white flecks in all layers of the stroma (Fig. 2 ) (8, 9) . CFD patients are usually asymptomatic and have normal vision, although mild photophobia has been reported by some patients. CFD can appear by age 2 years but, in general, the disease is non-progressive. Histologically abnormal keratocytes are present, which contain intracytoplasmic vesicles packed with complex lipids and acid mucopolysaccharides. In 2005, Li et al. (8) identified various mutations of PIPKIII in 8 of 10 families with CFD. Thereafter, a novel PIPKIII mutation was found in a Greek family with CFD (9) . Although PtdIns(3,5)P 2 levels were not determined in these patients, it was assumed that these mutations resulted in a loss of PIPKIII activity. If true, these findings would suggest that PIPKIII regulates the catabolism of lipids and glycosaminoglycans in keratocytes.
CharcotMarieTooth disease CharcotMarieTooth (CMT) disease is the most common form of inherited peripheral neuropathy. Although CMT is highly heterogeneous, both clinically and genetically, most patients show a slow, progressive degeneration of the muscles of the foot, lower leg, hand and forearm, as well as sensory problems. To date, more than 40 causative genes have been associated with CMT (http://www.molgen.ua.ac.be/ CMTMutations/Home/IPN.cfm), and three of them participate the metabolism of PtdIns(3,5)P 2 .
In 2000, Bolino et al. (10) studied several unrelated patients with CMT4B1 disease and identified mutations in the gene encoding the MTMR2 phosphoinositide phosphatase (Fig. 3) . MTMR2 can bind to the catalytically inactive MTMR family members MTMR5 and MTMR13, and these interactions trigger the enzymatic activity of MTMR2 (4). In 2003, two groups independently reported that mutations of MTMR13/SBF2 were associated with the closely related disorder CMT4B2 (Fig. 3) (11, 12) . This disease is an autosomal recessive demyelinating neuropathy characterized by myelin outfoldings. In mice, Chow et al. (13) discovered a spontaneous Sac3 mutation in pale tremor (plt) mutants, which exhibit CMT-like peripheral neuropathy. When CMT patients without mutations in known genes were screened for alterations to Sac3, several nonsense and missense mutations of the Sac3 gene were identified, leading to the designation of CMT4J for this disorder (Fig. 2 ). The phenotypes of CMT patients and plt mice suggest that PtdIns(3,5)P 2 has an essential role in the maintenance of the peripheral nervous system, including in myelination.
Centronuclear myopathy X-linked centronuclear myopathy (XLCNM; also known as myotubular myopathy) is a severe congenital muscle disorder caused by mutations in the MTM1 gene ( Fig. 3) (14) . Clinically, XLCNM patients exhibit severe hypotonia and generalized muscle weakness. Characteristic XLCNM muscle histopathology features muscle fibres that are small and rounded and contain centrally located nuclei, a phenotype reminiscent of fetal myotubes. Over 100 MTM1 mutations associated with XLCNM disease have been described (15) . Most are point mutations that truncate the protein but 25% are missense mutations affecting conserved residues.
In autosomal recessive forms of CNM, Tosch et al. (16) identified mutations in the gene encoding MTMR14/hJUMPY, which is a PtdIns(3)P and PtdIns(3,5)P 2 phosphatase with homology to MTM1. By sequencing the MTM1 and MTMR genes of patients with sporadic CNM, Tosch et al. identified a heterozygous missense variant (R336Q) of MTMR14 in the CX 5 R catalytic loop (Fig. 3 ). This alteration drastically inactivated MTMR14's phosphatase function, leading to the hypothesis that MTM1 and MTMR14 are involved in the normal development and/or structural organization of muscle fibres. However, more recent work has indicated that MTM1 has a role in the structural organization of muscle fibres that is independent of its enzymatic PtdIns consists of a glycerol backbone that is esterified at its sn1 and sn2 positions to two fatty acids, and linked via phosphate at its sn3 position to the D1 position of a D-myo-inositol head group. PtdIns(3,5)P 2 is phosphorylated at the D3 and D5 positions of the myo-inositol head group. activity (17) . Therefore, it remains uncertain whether lipid substrates of MTM1, such as PtdIns(3,5)P 2 and PtdIns(3)P, participate in muscle fibre regulation in vivo.
Mouse Models
Both spontaneous mouse mutants and genetically engineered strains have provided valuable information on potential physiological functions of PtdIns(3,5)P 2 in mammals. These mutants are listed in Table II .
PIPKIII
There are three types of mammalian PtdIns mono-phosphate (PIP) kinases that function in the synthesis of PtdIns derivatives, namely type I (PIPKI), type II (PIPKII) and type III (PIPKIII). For example, PtdIns(4,5)P 2 can be produced from PIP in two ways: either PIPKI phosphorylates the D5 position of PtdIns(4)P, or PIPKII phosphorylates the D4 position of PtdIns(5)P. In contrast, there is only one way to generate PtdIns(3,5)P 2 : the phosphorylation of the D5 position of PtdIns(3)P by PIPKIII. Mammalian PIPKIII, which is also known as PIKfyve, contains four domains of interest: Fab1p þ YOTB þ Vac1p þ EEA1 (FYVE), Dishevelled Egl-10 and pleckstrin (DEP), t-complex polypetide-1 (TCP-1) and PIPKc (Fig. 2) . The TCP-1 domain present in the middle of the PIPKIII protein is conserved from yeast to mammals. In all these species, this domain seems to be involved in the binding of PIPKIII to two regulatory proteins, Sac3 and Vac14.
At time of writing, the following four strains of genetically modified mice containing distinct PIPKIII mutations have been reported by ourselves and two other groups. Ikonomov et al. (18) used the Cre-loxP system to target PIPKIII exon 6, which encodes the FYVE domain. Zolov et al. (19) described a gene-trap mutant created by the insertion of the b-geo cassette into intron 17 of the PIPKIII gene. We generated constitutive PIPKIII knockout mice by replacing the first Tables I and II) . b-gal, b-galactosidase cassette; Neo, neomycin resistance cassette; b-geo, b-galactosidase and neomycin resistance cassette; NSE, neuron-specific enolase. Tables I and II). coding exon with the Neo/LacZ cassette, and conditional PIPKIII knockout animals by targeting exon 38, which encodes the kinase catalytic center (7). The PIPKIII gene-trap mouse of Zolov et al. is a hypomorph mutant possessing 10% of the normal PIPKIII protein level. Neonatal hypomorph mice display modest vacuolation in neural tissues, heart, lung, kidney, thymus and spleen. Hypomorph mice that survive beyond 2 weeks after birth develop more extensive vacuolation that leads to degeneration of the neural tissues, heart and kidney. We showed that complete deletion of PIPKIII causes early embryonic lethality at the post-implantation stage (7). Our PIPKIII-null mouse embryos died by embryonic day 8.5 due to functional defects in the visceral endoderm, an extraembryonic epithelial cell layer that encases the epiblast. Conditional mutants that lack PIPKIII specifically in the intestinal epithelium exhibit diarrhoea, bloody stool and inflamed and fibrotic gut epithelium (7). PIPKIII-deficient gut epithelial cells display severe vacuolation as was observed in the cells of PIPKIII hypomorph mutants. In addition, apical membrane proteins were not properly localized and accumulated in endosomal compartments in the PIPKIII-deficient epithelial cells. Taken together, these results demonstrate that PIPKIII is essential for the directional transport of apical proteins and apical membrane functions in polarized epithelial cells. Ikonomov et al. (18) have reported that systemic disruption of PipkIII leads to lethality before implantation at the 32-to 64-cell stage. Differences in the levels of maternally inherited PIPKIII protein within the embryos between Ikonomov's and our mutant mouse strains may explain the discrepancy in those embryonic phenotypes.
Sac3
Sac3 is the mammalian counterpart of yeast Fig4p, which is a 5 0 -phosphatase highly specific for PtdIns(3,5)P 2 . Interestingly, Sac3 binds to PIPKIII, an enzyme that catalyses the reverse reaction, and is necessary for full PIPKIII activation. In 2007, the presence of a natural mutation of Sac3 in plt mice was reported by Chow et al. This mutation arose from spontaneous insertion of the ETn2b transposon into intron 18 of the Sac3 gene, resulting in the complete loss of mature Sac3 mRNA (Fig. 2) (13) . Analysis of phosphoinositides in cultured fibroblasts from plt mice demonstrated a 3-fold reduction in PtdIns(3,5)P 2 . Physiologically, these mutants show severe tremor, abnormal gait, diluted pigmentation, reduced size, progressive loss of mobility and juvenile lethality. Examination of tissue pathology revealed enlarged cytoplasmic vacuoles in neurons, extensive loss of neurons from sensory and autonomic ganglia and a substantial reduction in the number of large-diameter myelinated axons in the sciatic nerve.
In 2011, Lenk et al. (20) created transgenic mice expressing Sac3 (I41T), a mutation identified in CMT4J patients. The phenotype of the Sac3 (I41T) mutant recapitulates the juvenile lethality and spongiform brain degeneration of plt mice in a dose-dependent manner. At the molecular level, the I41T mutation destabilizes the Sac3 protein by blocking its interaction with its stabilizing partner Vac14.
In 2012, Ferguson et al. (21) generated cell lineagespecific Sac3-expressing transgenic mice and mated them with plt mice. Analyses of the progeny showed that neuron-specific Sac3 expression was able to rescue the cellular and neurological defects of plt mice, including their spongiform degeneration and juvenile lethality, whereas astrocyte-specific Sac3 expression could not. Ferguson et al. also created neuron-specific Sac3-deficient mice using the Cre-loxP system and found that these animals developed spongiform degeneration and neurological abnormalities highly similar to those in plt mice. These findings suggest that neuronal but not glial Sac3 and PtdIns(3,5)P 2 are required to maintain an intracellular environment that prevents neuronal degeneration.
A difficulty with using the above mouse models to assess PtdIns(3,5)P 2 functions is that techniques like gene silencing or gene knockout, which result in substantial loss of the Sac3 protein, lead to destabilization and inactivation of PIPKIII, and thus a decrease in PtdIns(3,5)P 2 . Models are needed in which the physiological role of Sac3's phosphatase activity alone rather than its PIPKIII stabilization function can be examined. The development of a specific inhibitor of Sac3 phosphatase, or the generation of Sac3 knock-in mice lacking only the phosphatase activity of the Sac3 protein, will help to clarify this issue.
Vac14
Vac14 has no detectable enzymatic activity of its own but is an essential activator of PIPKIII (Fig. 2) . Thus, a loss of Vac14 would be expected to result in partial inhibition of PIPKIII activity and a moderate decrease in PtdIns The phenotypes of Vac14-deficient mice are very similar to those of Sac3-deficient mice. In addition, the Sac3 (I41T) mutant protein is unstable because it binds only inefficiently to Vac14. These observations suggest that the binding of Vac14 to Sac3 that stabilizes Sac3 is essential for efficient PtdIns(3,5)P 2 production by PIPKIII. This constellation of findings implies that PtdIns(3,5)P 2 is critical in the central nervous system as well as in the peripheral nervous system.
MTMRs
All active members of the MTMR family of phosphatases can dephosphorylate PtdIns(3,5)P 2 in vitro. Gene knockout mice have been generated for three such phosphatases: MTM1, MTMR2 and MTMR14 (Fig. 3) .
MTM1-deficient mice lacking exon 4 were generated by Buj-Bello et al. (26) using conventional gene targeting. These mice develop a generalized and progressive myopathy starting at around 4 weeks of age, with amyotrophy and accumulation of central nuclei in skeletal muscle fibres leading to death at 614 weeks. Muscle differentiation in MTM1-deficient mice occurs normally but there is a structural maintenance defect that results in characteristically abnormal fibres with centrally located nuclei. Skeletal muscle is the primary tissue affected by this disorder because skeletal musclespecific MTM1-deficient mice have a very similar phenotype to the null mutant (26) .
MTMR2-deficient mice have been generated using two distinct targeting strategies. In 2004, Bolino et al. (27) used the Cre-loxP system to generate conditional MTMR2 knockout mice bearing loxP sites flanking exon 6 of the MTMR2 gene. In 2005, Bonneick et al. (28) created constitutive MTMR2 knockout mice by replacing MTMR2 exons 9 to 13 with the b-geo cassette. Both mutants exhibited CMT4B-like progressive peripheral neuropathy characterized by myelin outfoldings. In wild-type mice, MTMR2 protein is expressed in both Schwann cells and neurons. When MTMR2 was disrupted only in Schwann cells and not in motor neurons, CMT4B neuropathy was again observed. These data indicate that loss of MTMR2 in Schwann cells is both sufficient and necessary to cause this disorder. Notably, genetrap mice lacking MTMR13, the binding partner and activator of MTMR2, exhibit a CMT4B-like disease (29, 30) .
MTMR14 (also known as muscle-specific inositol phosphatase) is a relatively new MTMR family member. Shen et al. (31) generated constitutive MTMR14 knockout mice that suffered from muscle weakness and fatigue. Muscles isolated from these mutants produced less contractile force, exhibited markedly prolonged relaxation, and showed exacerbated fatigue relative to normal muscles. MTMR14 deficiency also resulted in spontaneous Ca 2þ leakage from the sarcoplasmic reticulum. At the molecular level, PtdIns(3,5)P 2 was shown to bind to and directly activate ryanodine receptor 1, the Ca 2þ release channel of the sarcoplasmic reticulum. It is interesting that the other types of cation channels, namely transient receptor potential mucolipin-1 Ca 2þ channel and TPC Na þ channel, are also reportedly direct targets of PtdIns(3,5)P 2 (32, 33) . PtdIns(3,5)P 2 -mediated regulation of ion homeostasis at endomembrane compartments via these various channels could explain the diverse roles of PtdIns(3,5)P 2 in mammals. 
Conclusion

